The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase.
Vasoactive intestinal peptide (VIP) stimulates the neuroblastoma cell line (NMB) to proliferate. Neuropeptide activity can be inhibited by neutral endopeptidases that function intracellularly and in the extracellular milieu. NMB cells express neutral endopeptidase (NEP) activity that can be specifically inhibited by phosphoramidon (PA). Our data now show that phosphoramidon treatment increases the efficacy of VIP-stimulated neuroblastoma proliferation. These results suggest that membrane endopeptidases modulate VIP-associated cell proliferation and enhancement of endopeptidase activity may serve as a target for cancer therapy.
Wollman
Yoram
Y
Department of Nephrology, Tel Aviv Medical Center, 64239, Tel Aviv, Israel.
Blumberg
Shmariahu
S
Spungin
Anya
A
Brenneman
Douglas E
DE
Fridkin
Mati
M
Wollman
Jonathan
J
Iaina
Adrian
A
Gozes
Illana
I
D002455:Cell Division / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006020:Glycopeptides / Q000494:pharmacology; D006801:Humans; D015260:Neprilysin / Q000378:metabolism; D009447:Neuroblastoma / Q000473:pathology*; D014407:Tumor Cells, Cultured; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
D004791:Enzyme Inhibitors; D006020:Glycopeptides; D014660:Vasoactive Intestinal Peptide; D015260:Neprilysin; C008890:phosphoramidon